Our Team

Owen A. O’Connor, M.D., Ph.D.

Founder, Chair and Chief Executive Officer (CEO)

Owen is the Founder, Chair and Chief Executive Officer of Nouveau Biosciences. Under his leadership, Nouveau Biosciences has matured a platform to drug focused biotechnology company leveraging the latest advances in synthetic lethality screens, genomics and computational biology to produce a pipeline of novel, derisked nanotherapeutic drugs for cancer.  Their lead drug candidate, kromastat, has been shown to be a best-in-class and best-in-disease drug for the treatment of T-cell malignancies, pancreas cancer and a variety of aggressive forms of leukemia.  Nouveau has raised substantial capital to support its ambitious clinical programs, which has complimented many strategic collaborations around the world.  Dr. O’Connor is a world renowned physician-scientist who holds many patents on methods to treat cancer, and has led global regulatory approval of many drugs across a host of indications in cancer and autoimmune diseases.  Owen has studied and been on faculty at Cornell University Medical Center, Memorial Sloan Kettering Cancer Center and Columbia University to name a few. He has well over 300 publications, and has authored and edited many books on lymphoma and targeted drug therapies for cancer.  He is passionate about creating teams that think outside the box, and have a penchant for solving the field’s most significant challenges.

• Trial and employment attorney for over 30 years

• Past Federal Prosecutor in the U.S. Attorneys Office for the Eastern District of New York

• Extensive experience litigating complex cases across private equity and health care.

Rich Kushel, Senior Managing Director, is the Head of the Portfolio Management Group (PMG), which encompasses BlackRock’s liquid markets, active investing across Fixed Income, Equities and Multi-Asset Strategies. He is a member of the firm’s Global Management Committee, the Global Executive Committee, and co-chair of the GEC Investment Subcommittee.

Mr. Kushel’s prior roles include heading Multi-Asset Strategies, Global Fixed Income, Strategic Product Management, BlackRock Investment Stewardship, and the BlackRock Investment Institute. He has also served as Chief Product Officer and Deputy COO.

From 2009 to 2011, Mr. Kushel was based in London, and during that time served as Chairman of BlackRock’s International Businesses, responsible for the regional management of BlackRock’s businesses and operations outside the U.S. and Canada.

Prior to that assignment, Mr. Kushel held several other positions within the firm, including heading BlackRock’s International Institutional Business and BlackRock’s Alternatives and Wealth Management Groups. Prior to joining BlackRock in 1991, he was an Associate in the Financial Institutions Group at Prudential Securities.

Mr. Kushel currently serves as the Vice Chairman of the Advisory Council of the Freeman Spogli Institute for International Studies at Stanford University. Mr. Kushel holds a Bachelor of Science degree in Industrial Engineering from Stanford.

Since 1998, Robert Rosen has been a Managing Member of Greyhawke Capital Advisors LLC, a company which invests capital in, and applies management expertise to, selected investment opportunities generally involving net leased real estate properties. Greyhawke has also sponsored investments in multiple multi-family residential projects. Mr. Rosen was recently made a Director of Nouveau Biosciences, Inc. From 2012 until 2023, Robert Rosen also served as an independent director of KLS Diversified, a hedge fund that specialized in trading multiple debt strategies.

From 1990 through 1998, Mr. Rosen was Chief Executive Officer of Odin Management Company, LP and Newkirk Limited Partnership, two companies, which were formed to manage operations of 175 limited partnerships that owned approximately $5 Billion of commercial real estate properties that were syndicated by Integrated Resources, Inc. Control of these companies and the assets they controlled were sold in 1997 and 1998. Prior to 1990, Mr. Rosen practiced real estate and securities law as a senior partner at Hertzog, Calamari & Gleason and Rosen, Hacker & Nierenberg.

Mr. Rosen is a graduate of Columbia Law School where he was a Harlan Fiske Stone Scholar. He graduated cum laude with departmental honors in political science from the University of Massachusetts, Amherst and was a member of Phi Beta Kappa. Mr. Rosen was an Adjunct Senior Research Scholar for National Security Law at Columbia Law School advising the National Security Law Program. Between September 2014 and December 2019, Mr. Rosen taught a honor’s seminar on “Terrorism, War and Democracy” at the University of Massachusetts, Amherst.

Mr. Rosen was elected as a Director of the Cascade Village Metro District in Vail Colorado in 2024.

Mr. Rosen is a member of Dean’s Council at Columbia Law School and the Advisory Board of the Richman Center at Columbia University for Business, Law and Public Policy. He is also a director of the Blood Cancer United (formerly Leukemia and Lymphoma Society) where he was Chairman of the Finance Committee and is a member of the Therapy Acceleration Program and Investment Committee. He was recently appointed to the Advisory Board of Lawfare, a non-profit multimedia publication dedicated to Hard National Security Choices. He has served as a Director of Inspirica, one of the largest providers of services to the homeless in Connecticut and as a Director of the Partnership for After School Education which promotes and supports quality afterschool programs in New York City.

• President and Chief Medical Officer of Sarah Cannon Research Institute
• Executive Director, Drug Development for the research institute.
• International authority in drug development, clinical trials and regulatory process
• President Elect of ASCO (2019-2020)

• 30+ years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling
• Extensive experience in filing regulatory applications to FDA
• Has been involved in countless applications for hematopoietic agents, monoclonal antibodies and anti-cancer therapies

• Internationally recognized authority on early phase clinical trial design, pharmacokinetics, Project Optimus, and regulatory strategy
• Presently VP for Clinical Development at Pathos
• Previous Medical Lead for CRISPER technologies, Intellia Therapeutics, Inc.
• Physician Scientist, ASCO Cancer Research Committee

Thomas Loughran, M.D.

Director, Nanovations

• Director of UVA Comprehensive Cancer Center, an NCI Designated Cancer Center

• Most significantly funded research scientist in the history of the Commonwealth of Virginia

• Renowned cancer biologist

• Over 30 years experience and international authority in stem cell transplantation

• Founder of the John Theurer Cancer Center in Hackensack, N.J.

• More than 25 years experience creating biotechnology companies advancing innovative immunotherapies for the treatment of cancer.

   

• Past voting member and Chair of US FDA Oncology Drug Advisory Committee (ODAC)
• Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research
• Internationally renowned authority on the regulatory approval of drugs for hematologic malignancies and clinical trials